Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Interest Expenses (2021 - 2025)

BioNexus Gene Lab's Interest Expenses history spans 5 years, with the latest figure at $6482.0 for Q3 2025.

  • For Q3 2025, Interest Expenses rose 4.67% year-over-year to $6482.0; the TTM value through Sep 2025 reached $31042.0, up 44.17%, while the annual FY2024 figure was $21146.0, 51.81% up from the prior year.
  • Interest Expenses for Q3 2025 was $6482.0 at BioNexus Gene Lab, up from $4879.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $15157.0 in Q4 2023 and bottomed at -$17660.0 in Q4 2021.
  • The 5-year median for Interest Expenses is $3326.0 (2022), against an average of $1120.9.
  • The largest YoY upside for Interest Expenses was 305.55% in 2023 against a maximum downside of 231.18% in 2023.
  • A 5-year view of Interest Expenses shows it stood at -$17660.0 in 2021, then rose by 9.11% to -$16052.0 in 2022, then soared by 194.42% to $15157.0 in 2023, then dropped by 2.54% to $14772.0 in 2024, then crashed by 56.12% to $6482.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Interest Expenses are $6482.0 (Q3 2025), $4879.0 (Q2 2025), and $4909.0 (Q1 2025).